CA2968987C - Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof - Google Patents

Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof Download PDF

Info

Publication number
CA2968987C
CA2968987C CA2968987A CA2968987A CA2968987C CA 2968987 C CA2968987 C CA 2968987C CA 2968987 A CA2968987 A CA 2968987A CA 2968987 A CA2968987 A CA 2968987A CA 2968987 C CA2968987 C CA 2968987C
Authority
CA
Canada
Prior art keywords
cells
adcc
antibody
fusion protein
enhancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2968987A
Other languages
English (en)
French (fr)
Other versions
CA2968987A1 (en
Inventor
Chiang J. Li
Shyam UNNIRAMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1Globe Biomedical Co Ltd
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of CA2968987A1 publication Critical patent/CA2968987A1/en
Application granted granted Critical
Publication of CA2968987C publication Critical patent/CA2968987C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2968987A 2014-12-08 2015-12-08 Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof Active CA2968987C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462089097P 2014-12-08 2014-12-08
US62/089,097 2014-12-08
US201562200557P 2015-08-03 2015-08-03
US62/200,557 2015-08-03
PCT/US2015/064572 WO2016094456A1 (en) 2014-12-08 2015-12-08 Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Publications (2)

Publication Number Publication Date
CA2968987A1 CA2968987A1 (en) 2016-06-16
CA2968987C true CA2968987C (en) 2022-05-10

Family

ID=56108081

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2968987A Active CA2968987C (en) 2014-12-08 2015-12-08 Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Country Status (11)

Country Link
US (2) US12247062B2 (enExample)
EP (1) EP3230311B1 (enExample)
JP (2) JP7095992B2 (enExample)
KR (1) KR102654033B1 (enExample)
CN (1) CN107108718B (enExample)
AU (1) AU2015360642B2 (enExample)
CA (1) CA2968987C (enExample)
NZ (1) NZ732073A (enExample)
RU (1) RU2725807C2 (enExample)
SG (1) SG11201704124YA (enExample)
WO (1) WO2016094456A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
WO2016094456A1 (en) 2014-12-08 2016-06-16 1Globe Health Institute Llc Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
EP3796934A4 (en) * 2018-05-23 2022-04-06 Manysmart Therapeutics, Inc. BISPECIFIC T-LYMPHOCYTE ACTIVATOR AND USES THEREOF
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022004805A1 (ja) * 2020-06-30 2022-01-06 株式会社ガイアバイオメディシン Ｎｋ細胞と抗体との結合を安定化する方法、及びその利用
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
IL101147A (en) * 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
DK0826696T3 (da) * 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
KR101023367B1 (ko) * 1998-08-11 2011-03-18 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
UA93662C2 (uk) * 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
ATE535258T1 (de) * 2001-06-01 2011-12-15 Cornell Res Foundation Inc Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen
WO2004076621A2 (en) * 2003-02-27 2004-09-10 Yeda Research And Development Co. Ltd. Compositions of nucleic acids for treating and detecting influenza virus
WO2004108158A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-cd3 antibody
JP4948174B2 (ja) * 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
ZA200606410B (en) * 2004-02-16 2007-12-27 Micromet Ag Less immunogenic binding molecules
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
US20080219978A1 (en) * 2007-01-23 2008-09-11 Ellsworth Jeff L Soluble FcgammaRIA and related methods
US8043621B2 (en) * 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
JP6147670B2 (ja) 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 改善された半減期を有する修飾された抗体
JP2015505843A (ja) * 2011-12-15 2015-02-26 ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用
MX353382B (es) * 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
WO2016094456A1 (en) 2014-12-08 2016-06-16 1Globe Health Institute Llc Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Also Published As

Publication number Publication date
CN107108718B (zh) 2022-07-22
JP2018502068A (ja) 2018-01-25
CN107108718A (zh) 2017-08-29
US20220235115A1 (en) 2022-07-28
EP3230311A1 (en) 2017-10-18
EP3230311B1 (en) 2022-01-26
AU2015360642A1 (en) 2017-06-08
US12247062B2 (en) 2025-03-11
KR102654033B1 (ko) 2024-04-02
EP3230311A4 (en) 2018-05-30
RU2017124141A (ru) 2019-01-10
KR20170089003A (ko) 2017-08-02
SG11201704124YA (en) 2017-06-29
CA2968987A1 (en) 2016-06-16
JP7095992B2 (ja) 2022-07-05
JP2021035994A (ja) 2021-03-04
WO2016094456A1 (en) 2016-06-16
NZ732073A (en) 2019-04-26
AU2015360642B2 (en) 2019-04-04
RU2017124141A3 (enExample) 2019-06-19
RU2725807C2 (ru) 2020-07-06
US20170362299A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
US20220235115A1 (en) Soluble Universal ADCC-Enhancing Synthetic Fusion Gene and Peptide Technology and Its Use Thereof
US12559555B2 (en) Anti-LILRB4 antibodies and derivative products
US11008391B2 (en) Anti-PD-1 antibodies
JP2022065039A (ja) マクロファージ上のＦｃ受容体結合の破壊による抗ＳｌＲＰα抗体療法の効果増強
JP2021501606A (ja) Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
JP2015524821A (ja) システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
US20200255493A1 (en) Novel Synthetic Biology-Based ADCC Technology
EP4442701A1 (en) Combination of molecular switch regulation type chimeric antigen receptor cell and antibody, and use thereof
EP4445912A1 (en) P329g antibody targeting bcma, combination of same with chimeric antigen receptor cell, and use thereof
US20240409643A1 (en) Anti-nmdar2b antibodies, antibody-drug conjugates, and chimeric antigen receptors, and compositions and methods of use
Puri The Evaluation of MS4A4A and MS4A8B Expression in Hematopoietic Cells
HK1239703A1 (en) Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
WO2024169985A1 (zh) 靶向HER2/p95HER2的P329G抗体及其与嵌合抗原受体细胞的组合和应用
WO2024140836A1 (zh) 靶向nkg2d配体的融合蛋白与嵌合抗原受体细胞的组合及其用途
CN120322455A (zh) 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用
HK1229842A1 (en) Novel synthetic biology-based adcc technology

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201130